MarketCapExport financials
PMV Pharmaceuticals (PMVP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
PMV Pharmaceuticals Balance Sheet 2025-2011 | PMVP
Brief overview of PMV Pharmaceuticals's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Across five reporting periods, assets decreased -64.8%, from $331.6 million to $116.6 million, producing a negative trend.
Liability growth of -48.5% exceeded asset growth of -64.8%, increasing reliance on outside funding.
The equity-to-assets ratio is 89.8%, compared with 93.1% five periods ago. The balance sheet has a substantial internal cushion.
The period ended with net cash: net debt stood at -$37.1 million. This supports financial flexibility.
The cash share moved from 52% to 32.6%. A higher figure generally provides more room in an adverse scenario.
Retained earnings are negative at -$446.5 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Conclusion
PMV Pharmaceuticals's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet PMV Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-37.1 M | -39.7 M | -24.4 M | -94.3 M | -161 M | - | -73.3 M | -30.3 M | - | - | - | - | - | - | - |
Long Term Debt |
435 K | 838 K | 12.4 M | 13.4 M | 10.8 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
403 K | 352 K | 852 K | 528 K | 403 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 169 M | 107 M | - | - | - | - | - | - | - |
Total Current Liabilities |
11.4 M | 14.4 M | 14 M | 10.8 M | 12.2 M | 6.41 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
11.8 M | 15.2 M | 26.5 M | 24.3 M | 23 M | 6.41 M | 174 M | 110 M | - | - | - | - | - | - | - |
Retained Earnings |
-446 M | -369 M | -310 M | -241 M | -168 M | -110 M | -75.4 M | -50.1 M | - | - | - | - | - | - | - |
Total Assets |
117 M | 191 M | 252 M | 270 M | 332 M | 366 M | 103 M | 63.5 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
38 M | 40.9 M | 37.7 M | 108 M | 172 M | 361 M | - | - | - | - | - | - | - | - | - |
Book Value |
105 M | 176 M | 226 M | 246 M | 309 M | 359 M | -70.5 M | -46.1 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
105 M | 176 M | 226 M | 246 M | 309 M | 359 M | -70.5 M | -46.1 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet PMV Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 541 K | 643 K | 742 K | 838 K | 12 M | 11.8 M | - | 12.4 M | 12.7 M | 13 M | 13.2 M | 13.4 M | 12.1 M | 12.2 M | 11.5 M | 10.8 M | 10.7 M | 10.6 M | 302 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.6 M | 12.8 M | 12.2 M | 10.5 M | 15.2 M | 25.6 M | 23.2 M | - | 26.5 M | 23.4 M | 24.4 M | 23.8 M | 24.3 M | 23.8 M | 23.6 M | 23.2 M | 23 M | 19.2 M | 18.1 M | 6.1 M | 6.41 M | 6.41 M | 6.41 M | 6.41 M | 4.57 M | 4.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-464 M | -428 M | -407 M | -386 M | -369 M | -346 M | -326 M | - | -310 M | -294 M | -278 M | -260 M | -241 M | -222 M | -203 M | -186 M | -168 M | -149 M | -134 M | -121 M | -110 M | -110 M | -110 M | -110 M | -75.4 M | -75.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
96.6 M | 134 M | 153 M | 171 M | 191 M | 223 M | 238 M | - | 252 M | 261 M | 242 M | 254 M | 270 M | 285 M | 301 M | 315 M | 332 M | 344 M | 356 M | 354 M | 366 M | 366 M | 366 M | 366 M | 103 M | 103 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
39.1 M | 36.3 M | 44.1 M | 51.3 M | 40.9 M | 48.8 M | 48.5 M | - | 37.7 M | 52.1 M | 68.2 M | 143 M | 108 M | 99.8 M | 87.1 M | 116 M | 172 M | 177 M | 189 M | 209 M | 361 M | 361 M | 361 M | 361 M | 73.3 M | 73.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
88 M | 121 M | 141 M | 160 M | 176 M | 198 M | 214 M | - | 226 M | 238 M | 218 M | 230 M | 246 M | 261 M | 277 M | 292 M | 309 M | 325 M | 338 M | 348 M | 359 M | 359 M | 359 M | 359 M | 98.5 M | 98.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
88 M | 121 M | 141 M | 160 M | 176 M | 198 M | 214 M | 213 M | 226 M | 238 M | 218 M | 230 M | 246 M | 261 M | 277 M | 292 M | 309 M | 325 M | 338 M | 348 M | 359 M | 359 M | 359 M | 359 M | -70.5 M | -70.5 M | -57.7 M | -51.9 M | -46.1 M | - | - | - | -29.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of PMV Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Japan
Israel
Canada
Schweiz
China
Germany
Britain
France